T-Therapeutics Ltd
Robert Tansley is a Partner at Cambridge Innovation Capital plc, focusing on investments in life sciences and technology companies affiliated with the University of Cambridge since January 2014. Tansley serves as a Board Member for various organizations, including T-Therapeutics Ltd, Pretzel Therapeutics, Exvastat, Microbiotica, and ABCODIA LIMITED, all dedicated to advancing medical treatments and technologies. Additionally, Tansley held roles at PetMedix and CMR Surgical, contributing to innovations in animal health and minimally invasive surgery, respectively. Tansley also has experience as a Board Observer at Carrick Therapeutics and has served on the board of Inivata, a liquid biopsy company. Tansley holds an M.Phil in Epidemiology & Biostatistics from the University of Cambridge, an MBA from London Business School, and an MBBS from UCL, along with several other medical and pharmaceutical qualifications.
This person is not in the org chart
This person is not in any teams
T-Therapeutics Ltd
T-Therapeutics is a venture-backed company on a mission to unlock the power of T cells to treat chronic and infectious diseases. Based on technology from Professor Allan Bradley’s laboratory in Cambridge University’s Department of Medicine, T-Therapeutics has secured significant investment from a blue-chip syndicate of investors to support its drug discovery efforts and prepare candidates for clinical development. T-Therapeutics was founded in 2022, and we are at the very beginning of our journey to develop transformative T cell derived medicines. To realise our ambition, we are currently building facilities, recruiting staff, and establishing our research operations.